Literature DB >> 23035696

Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer.

Hamed Ahmadi1, Anirban P Mitra, George A Abdelsayed, Jie Cai, Hooman Djaladat, Harman M Bruins, Siamak Daneshmand.   

Abstract

OBJECTIVE: To develop a model that integrates the clinical and pathological information prior to radical cystectomy to increase the accuracy of current clinical stage in prediction of pathological stage in patients with bladder cancer (BC) using a modelling approach called principal component analysis (PCA). PATIENTS AND METHODS: In a single-centre retrospective study, demographic and clinicopathological information of 1186 patients with clinically organ-confined (OC) BC was reviewed. Putative predictors of post-cystectomy pathological stage were identified using a stepwise logistic regression model. Patients were randomly divided into training data set (two-thirds of the study population, 790 patients) and test data set (one-third of the study population, 396 patients). The PCA method was used to develop the model in the training data set and the cut-off point (PCA score) to differentiate pathological OC disease from extravesical disease was determined. The model was then applied to the test data set without recalculation.
RESULTS: In all, 685 patients (57.7%) had pathological OC disease. Age, clinical stage, number of intravesical treatments, lymphovascular invasion, multiplicity of tumours, hydronephrosis and palpable mass were incorporated into the PCA model as predictors of pathological stage. The sensitivity and specificity of the PCA model in the test data set were 62.8% (95% CI 55.6%-68.1%) and 68.9% (95% CI 60.8%-76.0%), respectively. The positive and negative predictive values were 75.8% (95% CI 69.0%-81.6%) and 51.5% (95% CI 44.4%-58.5%), respectively.
CONCLUSIONS: The pre-cystectomy PCA model improved the ability to differentiate OC disease from extravesical BC and especially decreased the under-staging rate. The pre-cystectomy PCA model represented a user-friendly staging aid without the need for sophisticated statistical interpretation.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2012        PMID: 23035696     DOI: 10.1111/j.1464-410X.2012.11502.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

Review 1.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.

Authors:  Romain Mathieu; Ilaria Lucca; Morgan Rouprêt; Alberto Briganti; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

Review 2.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

3.  Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma.

Authors:  Manuel S Eisenberg; John C Cheville; R Houston Thompson; Dharam Kaushik; Christine M Lohse; Stephen A Boorjian; Brian A Costello; Bradley C Leibovich
Journal:  J Urol       Date:  2013-01-23       Impact factor: 7.450

4.  External validation of existing nomograms predicting lymph node metastases in cystectomized patients.

Authors:  Miroslav M Stojadinovic; Rade I Prelevic
Journal:  Int J Clin Oncol       Date:  2014-04-11       Impact factor: 3.402

5.  Scoring system for prediction of lymph node metastasis in radical cystectomy cohort.

Authors:  Miroslav M Stojadinović; Rade Prelević; Arso Vukićević
Journal:  Int Urol Nephrol       Date:  2014-01-29       Impact factor: 2.370

6.  Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases.

Authors:  Anirban P Mitra; Jie Cai; Gus Miranda; Sumeet Bhanvadia; David I Quinn; Anne K Schuckman; Hooman Djaladat; Siamak Daneshmand
Journal:  J Urol       Date:  2021-11-08       Impact factor: 7.450

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.